Trial record 1 of 1 for:    NCT01853046
Previous Study | Return to List | Next Study

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01853046
First received: May 10, 2013
Last updated: August 7, 2015
Last verified: August 2015
  Purpose
To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)

Condition Intervention Phase
Neoplasms
Drug: Regorafenib (Stivarga, BAY73-4506)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • AUC(0-tlast) [area under the concentration-time curve after single dose from time zero to the last data point >LLOQ (lower limit of quantification)] for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0-24 hours post administration) for metabolites M-7 and M-8 [ Time Frame: Days 1-2: 0-24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor response assessment for measurable lesions according to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors) [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
  • Assessment of bone metastases by scintigraphy (bone scan) [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
  • AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AUC(0-24) (AUC from time zero to 24 hours p.a. after first-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • Cmax (maximum drug concentration in plasma after first dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • tmax (time to reach maximum drug concentration in plasma after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • tlast (time of last data point >LLOQ) after single dose for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • t1/2 (half-life associated with the terminal slope) after single dose for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • CL/F (total body clearance of drug after extravascular administration) after single dose for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • Vz/F (apparent volume of distribution during terminal phase after single oral administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • Cmax,md (Cmax after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • tlast,md (tlast after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on population PK model

  • AUC(0-tlast)md ((AUC (0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose ] [ Designated as safety issue: No ]
    based on population PK model evaluation and on the nominal dosing schedule

  • RACmax (Accumulation ratio calculated from Cmax,md and Cmax) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • RAAUC (Accumulation ratio calculated from AUC(0-24)md and AUC(0-24)) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • RLin (Linearity factor calculated as ratio from AUC(0-24)md and AUC) for regorafenib and its pharmacologically active metabolites M-2 and M-5 [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(0-24)md (AE,ur(0-24) after multiple-dose administration) for metabolites M-7 and M-8 [ Time Frame: Days 21-22: 0-24 hours ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(0-10) Stage 1 (amount of drug excreted via urine during the collection interval 0-10 hours post administration) for metabolites M-7 and M-8 [ Time Frame: Days 1-2: 0-10 hours ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(10-24) Stage 1 ((amount of drug excreted via urine during the collection interval 10-24 hours post administration) for metabolites M-7 and M-8 [ Time Frame: Days 1-2: 10-24 hours ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(0-10) Stage 2 for metabolites M-7 and M-8 [ Time Frame: Days 21-22: 0-10 hours ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation

  • AE,ur(10-24) Stage 2 for metabolites M-7 and M-8 [ Time Frame: Days 21-22: 10-24 hours ] [ Designated as safety issue: No ]
    based on non-compartmental PK evaluation


Enrollment: 24
Study Start Date: June 2013
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regorafenib (severe impairment)
Cancer subjects with severe renal impairment
Drug: Regorafenib (Stivarga, BAY73-4506)
Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
Experimental: Regorafenib (normal impairment)
Cancer subjects with normal or mildly impaired renal function
Drug: Regorafenib (Stivarga, BAY73-4506)
Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with histologically confirmed, locally advanced or metastatic, refractory solid tumors who are not candidates for standard therapy
  • Male or female subject ≥ 18 years of age
  • Women of childbearing potential must have a negative urine pregnancy test performed within 7 days before start of study treatment
  • Life expectancy at least 8 weeks
  • Adequate bone marrow, and liver function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
  • For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:

    • Estimated creatinine clearance (CLcr) ≥ 60 mL/min as calculated using the Cockcroft-Gault equation
  • For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:

    • CLcr 15-29 mL/min as calculated using the Cockcroft-Gault equation

Exclusion Criteria:

  • Symptomatic metastatic brain or meningeal tumors
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
  • History of organ allograft
  • Non-healing wound, skin ulcer, or bone fracture
  • Pheochromocytoma
  • Uncontrolled concurrent medical illness including uncontrolled hypertension
  • History of cardiac disease
  • Pleural effusion or ascites that causes respiratory compromise
  • Interstitial lung disease with ongoing signs and symptoms at the time of screening
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication
  • Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding event NCI-CTCAE Grade ≥ 3 or higher within 4 weeks of start of investigational treatment
  • Dehydration NCI-CTCAEversion 4.0 Grade ≥ 1
  • Unresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not reversible due to oxaliplatin)
  • Seizure disorder requiring anticonvulsant therapy (such as steroids or anti-epileptics)
  • For subjects with SEVERELY IMPAIRED renal function:

    • Renal failure requiring hemo- or peritoneal dialysis
    • Acute renal failure
    • Acute nephritis
    • Nephrotic syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01853046

Locations
United States, California
Los Angeles, California, United States, 90033
United States, Colorado
Aurora, Colorado, United States, 80045
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, New Hampshire
Lebanon, New Hampshire, United States, 03756
United States, New York
Buffalo, New York, United States, 14263-0001
Canada, Alberta
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Hamilton, Ontario, Canada, L8V 5C2
Canada, Quebec
Montreal, Quebec, Canada, H2L 4M1
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01853046     History of Changes
Other Study ID Numbers: 16653 
Study First Received: May 10, 2013
Last Updated: August 7, 2015
Health Authority: Canada: Health Canada
United States: Food and Drug Administration

Keywords provided by Bayer:
Regorafenib
pharmacokinetics
safety
severe renal impairment
Solid tumors

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on August 23, 2016